FIBRX DERM
FIBRX Derm is committed to the development of decorin, an anti-scarring therapy, for Dystrophic Epidermolysis Bullosa, a devastating, genetic, skin blistering disease. Decorin, a naturally occurring protein, binds collagen and facilitates the proper development, maintenance, and repair of structural components of the extracellular matrix. They are developing a gel formulation of human recombinant Decorin, an engineered form of the natural anti-scarring protein, to promote healthy tissue regeneration and reduce excessive scarring.
FIBRX DERM
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.fibrx-derm.com
Total Employee:
1+
Status:
Active
Contact:
(617) 520-6662
Total Funding:
1.75 M USD
Technology used in webpage:
Google Apps For Business Wix Wix DNS
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Current Employees Featured
Founder
